The transfer of CS Healthcare’s members and business to Bupa has received final regulatory approval required for it to go ahead on 1 January 2021.
The Prudential Regulatory Authority today published its approval, which follows clearance from the Competition and Markets Authority and the Channel Islands Competition and Regulatory Authorities. CS Healthcare’s members also overwhelmingly voted in favour of the transfer at the September 2020 AGM.
Alex Perry, CEO, Bupa UK Insurance said: “We’re pleased that the PRA has approved the transfer of CS Healthcare’s business and members to Bupa, which is the final regulatory step. We’re very much looking forward to welcoming CS Healthcare’s members and people to Bupa on 1 January 2021.
“The transfer offers a number of benefits to CS Healthcare members, including reassurance over the sustainability of their health insurance, enhanced policy benefits and greater access to health and wellbeing benefits to support their physical and mental health.”
When they renew onto a Bupa policy, CS Healthcare’s 17,500 members will benefit from greater access to even more health and wellbeing services. These include Bupa’s specialist support for cancer* and cardiac care, digital GP service, and direct access to treatment for a wide range of conditions without needing to see a GP first. They’ll also benefit from enhanced policy benefits and Bupa’s market-leading mental health cover, to support this important aspect of their overall health and wellbeing.
Notes to editor
* where customers have chosen to include cancer cover
About Bupa
Bupa's purpose is helping people live longer, healthier, happier lives and making a better world.
We are an international healthcare company serving over 31 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers.
We directly employ around 85,000 people, principally in the UK, Australia, Spain, Chile, Poland, New Zealand, Hong Kong SAR, Turkey, Brazil, Mexico, the US, Middle East and Ireland. We also have associate businesses in Saudi Arabia and India.
